Cellular dormancy in minimal residual disease following targeted therapy

BACKGROUND: Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades. While clinical latency has been postulated to reflect the ability of residual tumor cells to persist in a dormant state, this hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruth, Jason R., Pant, Dhruv K., Pan, Tien-chi, Seidel, Hans E., Baksh, Sanjeethan C., Keister, Blaine A., Singh, Rita, Sterner, Christopher J., Bakewell, Suzanne J., Moody, Susan E., Belka, George K., Chodosh, Lewis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178846/
https://www.ncbi.nlm.nih.gov/pubmed/34088357
http://dx.doi.org/10.1186/s13058-021-01416-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178846/
https://www.ncbi.nlm.nih.gov/pubmed/34088357
http://dx.doi.org/10.1186/s13058-021-01416-9

Ejemplares similares